<!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-2004-03-09.dtd" [ ]>
<sequence-cwu id="SEQLST-1">
<publication-reference>
<document-id>
<country>US</country>
<doc-number>08623358</doc-number>
<kind>B2</kind>
<date>20140107</date>
</document-id>
</publication-reference>
<number>1</number>
<sequence-list-new-rules>
<s100>
<s160>377</s160>
</s100>
<s200>
<s210>1</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 1
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>2</s210>
<s211>330</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 2
Ala Ser Thr Lys Gly Pro Ser Val Phe Phe Leu Ala Pro Ser Ser Lys
1               5                   10                  15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20                  25                  30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35                  40                  45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50                  55                  60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65                  70                  75                  80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85                  90                  95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
            100                 105                 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
        115                 120                 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
    130                 135                 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145                 150                 155                 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
                165                 170                 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
            180                 185                 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
        195                 200                 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
    210                 215                 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225                 230                 235                 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
                245                 250                 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
            260                 265                 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
        275                 280                 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
    290                 295                 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305                 310                 315                 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
                325                 330
</s400>
<s200>
<s210>3</s210>
<s211>330</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IgG1 constant region mutant</s223>
</s220>
</s200>
<s400> 3
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1               5                   10                  15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20                  25                  30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35                  40                  45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50                  55                  60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65                  70                  75                  80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85                  90                  95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
            100                 105                 110
Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
        115                 120                 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
    130                 135                 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145                 150                 155                 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
                165                 170                 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
            180                 185                 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
        195                 200                 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
    210                 215                 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225                 230                 235                 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
                245                 250                 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
            260                 265                 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
        275                 280                 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
    290                 295                 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305                 310                 315                 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
                325                 330
</s400>
<s200>
<s210>4</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 4
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1               5                   10                  15
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
            20                  25                  30
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
        35                  40                  45
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
    50                  55                  60
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65                  70                  75                  80
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
                85                  90                  95
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
            100                 105
</s400>
<s200>
<s210>5</s210>
<s211>105</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 5
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
1               5                   10                  15
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
            20                  25                  30
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
        35                  40                  45
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
    50                  55                  60
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
65                  70                  75                  80
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
                85                  90                  95
Lys Thr Val Ala Pro Thr Glu Cys Ser
            100                 105
</s400>
<s200>
<s210>6</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH2-70/JH6 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 6
Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1               5                   10                  15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser
            20                  25                  30
</s400>
<s200>
<s210>7</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH2-70/JH6 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 7
Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala
1               5                   10
</s400>
<s200>
<s210>8</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH2-70/JH6 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 8
Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr
1               5                   10                  15
Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>9</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH2-70/JH6 FR4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 9
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>10</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH2-26/JH6 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 10
Glu Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
1               5                   10                  15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser
            20                  25                  30
</s400>
<s200>
<s210>11</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH2-26/JH6 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 11
Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val Val Leu Thr
1               5                   10                  15
Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>12</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH3-72/JH6 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 12
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
            20                  25                  30
</s400>
<s200>
<s210>13</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH3-72/JH6 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 13
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly
1               5                   10
</s400>
<s200>
<s210>14</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH3-72/JH6 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 14
Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln
1               5                   10                  15
Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>15</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH3-21/JH6 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 15
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
            20                  25                  30
</s400>
<s200>
<s210>16</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH3-21/JH6 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 16
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
1               5                   10
</s400>
<s200>
<s210>17</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH3-21/JH6 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 17
Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln
1               5                   10                  15
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>18</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH1-69/JH6 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 18
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1               5                   10                  15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser
            20                  25                  30
</s400>
<s200>
<s210>19</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH1-69/JH6 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 19
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly
1               5                   10
</s400>
<s200>
<s210>20</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH1-69/JH6 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 20
Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu
1               5                   10                  15
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>21</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH1-18/JH6 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 21
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
            20                  25                  30
</s400>
<s200>
<s210>22</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>VH1-18/JH6 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 22
Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu
1               5                   10                  15
Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>23</s210>
<s211>23</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>B3/JK4 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 23
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1               5                   10                  15
Glu Arg Ala Thr Ile Asn Cys
            20
</s400>
<s200>
<s210>24</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>B3/JK4 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 24
Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>25</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>B3/JK4 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 25
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1               5                   10                  15
Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>26</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>B3/JK4 FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 26
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
1               5                   10
</s400>
<s200>
<s210>27</s210>
<s211>23</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L2/JK4 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 27
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1               5                   10                  15
Glu Arg Ala Thr Leu Ser Cys
            20
</s400>
<s200>
<s210>28</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L2/JK4 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 28
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>29</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L2/JK4 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 29
Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
1               5                   10                  15
Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>30</s210>
<s211>23</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L15/JK4 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 30
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15
Asp Arg Val Thr Ile Thr Cys
            20
</s400>
<s200>
<s210>31</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L15/JK4 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 31
Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>32</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L15/JK4 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 32
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1               5                   10                  15
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>33</s210>
<s211>23</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L5/JK4 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 33
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1               5                   10                  15
Asp Arg Val Thr Ile Thr Cys
            20
</s400>
<s200>
<s210>34</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>L5/JK4 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 34
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>35</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 35
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
            20                  25                  30
</s400>
<s200>
<s210>36</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 36
Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
1               5                   10
</s400>
<s200>
<s210>37</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 37
Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys
1               5                   10                  15
Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>38</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59/JH FR4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 38
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>39</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-66 FW1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 39
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser
            20                  25                  30
</s400>
<s200>
<s210>40</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-66 FW2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 40
Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
1               5                   10
</s400>
<s200>
<s210>41</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-66 FW3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 41
Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe Tyr Leu Gln
1               5                   10                  15
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>42</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-66/JH FW4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 42
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>43</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 43
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
            20                  25                  30
</s400>
<s200>
<s210>44</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 44
Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
1               5                   10
</s400>
<s200>
<s210>45</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 45
Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Tyr Leu Lys
1               5                   10                  15
Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>46</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV4-59/JH FR4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 46
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>47</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV5-51 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 47
Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu
1               5                   10                  15
Ser Leu Lys Ile Ser Cys Lys Val Ser Gly Gly Ser Ile Ser
            20                  25                  30
</s400>
<s200>
<s210>48</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV5-51 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 48
Trp Ile Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Ile Gly
1               5                   10
</s400>
<s200>
<s210>49</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV5-51 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 49
Gln Val Thr Ile Ser Val Asp Thr Ser Phe Asn Thr Phe Phe Leu Gln
1               5                   10                  15
Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>50</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV5-51/JH FR4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 50
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>51</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV2-70 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 51
Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1               5                   10                  15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
            20                  25                  30
</s400>
<s200>
<s210>52</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV2-70 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 52
Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
1               5                   10
</s400>
<s200>
<s210>53</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV2-70 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 53
Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Val Leu Thr
1               5                   10                  15
Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
            20                  25                  30
</s400>
<s200>
<s210>54</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV2-70/JH FR4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 54
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>55</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-15 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 55
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Ser Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg
            20                  25                  30
</s400>
<s200>
<s210>56</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-15 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 56
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
1               5                   10
</s400>
<s200>
<s210>57</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-15 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 57
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
1               5                   10                  15
Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
            20                  25                  30
</s400>
<s200>
<s210>58</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-15/JH FR4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 58
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>59</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-43 FR1 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 59
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly
            20                  25                  30
</s400>
<s200>
<s210>60</s210>
<s211>14</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-43 FR2 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 60
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
1               5                   10
</s400>
<s200>
<s210>61</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-43 FR3 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 61
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
1               5                   10                  15
Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
            20                  25                  30
</s400>
<s200>
<s210>62</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGHV3-43/JH FR4 heavy chain acceptor sequence</s223>
</s220>
</s200>
<s400> 62
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
1               5                   10
</s400>
<s200>
<s210>63</s210>
<s211>22</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 63
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys
            20
</s400>
<s200>
<s210>64</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 64
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>65</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 65
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Gly Thr Gln Pro Met Asp Glu Ala Asp Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>66</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1/JL FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 66
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
1               5                   10
</s400>
<s200>
<s210>67</s210>
<s211>22</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 67
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys
            20
</s400>
<s200>
<s210>68</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 68
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>69</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 69
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Gly Thr Gln Pro Met Asp Glu Ala Asp Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>70</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1/JL FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 70
Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
1               5                   10
</s400>
<s200>
<s210>71</s210>
<s211>21</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 71
Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr
1               5                   10                  15
Ala Ser Ile Thr Cys
            20
</s400>
<s200>
<s210>72</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 72
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>73</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 73
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Gly Thr Gln Pro Met Asp Glu Ala Asp Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>74</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1/JL FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 74
Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
1               5                   10
</s400>
<s200>
<s210>75</s210>
<s211>22</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 75
Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys
            20
</s400>
<s200>
<s210>76</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 76
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>77</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 77
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Gly Thr Gln Thr Met Asp Glu Ala Asp Tyr Leu Cys
            20                  25                  30
</s400>
<s200>
<s210>78</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1/JL FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 78
Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly
1               5                   10
</s400>
<s200>
<s210>79</s210>
<s211>23</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV6D-21 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 79
Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1               5                   10                  15
Glu Lys Val Thr Ile Thr Cys
            20
</s400>
<s200>
<s210>80</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV6D-21 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 80
Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>81</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV6D-21 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 81
Gly Val Pro Ser Arg Phe Ser Gly Ser Asn Ser Gly Asp Asp Ala Thr
1               5                   10                  15
Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>82</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV6D-21/JK FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 82
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
1               5                   10
</s400>
<s200>
<s210>83</s210>
<s211>23</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV3D-15 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 83
Glu Tyr Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1               5                   10                  15
Glu Arg Ala Thr Leu Ser Cys
            20
</s400>
<s200>
<s210>84</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV3D-15 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 84
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>85</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV3D-15 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 85
Asp Ile Pro Ala Arg Phe Ser Gly Ser Asn Ser Gly Asp Glu Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>86</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV3D-15/JK FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 86
Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
1               5                   10
</s400>
<s200>
<s210>87</s210>
<s211>23</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV4-1 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 87
Asp Tyr Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1               5                   10                  15
Glu Arg Ala Thr Ile Asn Cys
            20
</s400>
<s200>
<s210>88</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV4-1 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 88
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>89</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV4-1 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 89
Gly Ile Pro Asp Arg Phe Ser Gly Ser Asn Ser Gly Asp Asp Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
            20                  25                  30
</s400>
<s200>
<s210>90</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGKV4-1/JK FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 90
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
1               5                   10
</s400>
<s200>
<s210>91</s210>
<s211>22</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 91
Leu Pro Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys
            20
</s400>
<s200>
<s210>92</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 92
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>93</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 93
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Gly Thr Gln Thr Met Asp Glu Ala Asp Tyr Leu Cys
            20                  25                  30
</s400>
<s200>
<s210>94</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1/JL FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 94
Phe Gly Gly Gly Thr Lys Val Thr Val Leu
1               5                   10
</s400>
<s200>
<s210>95</s210>
<s211>22</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR1 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 95
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys
            20
</s400>
<s200>
<s210>96</s210>
<s211>15</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR2 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 96
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1               5                   10                  15
</s400>
<s200>
<s210>97</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1 FR3 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 97
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr
1               5                   10                  15
Leu Thr Ile Ser Gly Thr Gln Thr Met Asp Glu Ala Asp Tyr Leu Cys
            20                  25                  30
</s400>
<s200>
<s210>98</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>IGLV3-1/JL FR4 light chain acceptor sequence</s223>
</s220>
</s200>
<s400> 98
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
1               5                   10
</s400>
<s200>
<s210>99</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-H1 consensus sequence</s223>
</s220>
</s200>
<s400> 99
Xaa Xaa Xaa Tyr Xaa Trp Gly
1               5
</s400>
<s200>
<s210>100</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-H2 consensus sequence</s223>
</s220>
</s200>
<s400> 100
Asp Ile Xaa Tyr Xaa Gly Xaa Thr Tyr Tyr Asn Pro Ser Leu Lys Xaa
1               5                   10                  15
</s400>
<s200>
<s210>101</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-H3 consensus sequence</s223>
</s220>
</s200>
<s400> 101
Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Asp Xaa
1               5                   10
</s400>
<s200>
<s210>102</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-L1 consensus sequence</s223>
</s220>
</s200>
<s400> 102
Ser Gly Xaa Xaa Leu Gly Xaa Lys Tyr Xaa Ser
1               5                   10
</s400>
<s200>
<s210>103</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-L2 consensus sequence</s223>
</s220>
</s200>
<s400> 103
Xaa Asp Xaa Xaa Arg Pro Ser
1               5
</s400>
<s200>
<s210>104</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-L3 consensus sequence</s223>
</s220>
</s200>
<s400> 104
Gln Ala Trp Asp Xaa Xaa Xaa Xaa Val
1               5
</s400>
<s200>
<s210>105</s210>
<s211>5</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-H1 consensus sequence</s223>
</s220>
</s200>
<s400> 105
Xaa Xaa Trp Met Xaa
1               5
</s400>
<s200>
<s210>106</s210>
<s211>17</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-H2 consensus sequence</s223>
</s220>
</s200>
<s400> 106
Xaa Ile Ser Xaa Asp Gly Xaa Xaa Xaa Xaa Xaa Ala Asp Ser Val Lys
1               5                   10                  15
Gly
</s400>
<s200>
<s210>107</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-H3 consensus sequence</s223>
</s220>
</s200>
<s400> 107
Ala Xaa Gly Xaa Asn Xaa Gly Xaa Asp Xaa
1               5                   10
</s400>
<s200>
<s210>108</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-L1 consensus sequence</s223>
</s220>
</s200>
<s400> 108
Ser Xaa Asp Xaa Leu Gly Xaa Xaa Tyr Xaa Ser
1               5                   10
</s400>
<s200>
<s210>109</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-L2 consensus sequence</s223>
</s220>
</s200>
<s400> 109
Gln Asp Xaa Xaa Arg Pro Ser
1               5
</s400>
<s200>
<s210>110</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody CDR-L3 consensus sequence</s223>
</s220>
</s200>
<s400> 110
Gln Xaa Trp Asp Xaa Xaa Xaa Xaa Val
1               5
</s400>
<s200>
<s210>111</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 111
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Arg Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>112</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 112
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Ser Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Ile Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Ser Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>113</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 113
Leu Pro Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Ala Asp Lys Leu Gly Thr Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Ala Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Leu Cys Gln Ser Trp Asp Arg Ser Asp Val Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>114</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>mutations of antibody E9 VH sequence</s223>
</s220>
</s200>
<s400> 114
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Xaa Xaa Xaa
            20                  25                  30
Xaa Tyr Tyr Trp Gly Trp Ile Arg Gln Xaa Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Xaa Tyr Xaa Gly Xaa Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Xaa Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Xaa Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Asp Xaa Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>115</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>mutations of antibody E9 VL sequence</s223>
</s220>
</s200>
<s400> 115
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Xaa Xaa Leu Gly Xaa Lys Tyr Xaa
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Xaa Asp Xaa Xaa Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Xaa Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Xaa Xaa Xaa Xaa Val
                85                  90                  95
Phe Gly Xaa Gly Thr Xaa Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>116</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>affinity matured DLL4 antibody E9.4 VH region</s223>
</s220>
</s200>
<s400> 116
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Tyr Asp Val Ser Leu Gly Gly Ser Ser Asp His Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>117</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.4 CDR-H1</s223>
</s220>
</s200>
<s400> 117
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>118</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.4 CDR-H2</s223>
</s220>
</s200>
<s400> 118
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>119</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.4 CDR-H3</s223>
</s220>
</s200>
<s400> 119
Tyr Asp Val Ser Leu Gly Gly Ser Ser Asp His
1               5                   10
</s400>
<s200>
<s210>120</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 VH region</s223>
</s220>
</s200>
<s400> 120
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Ala Val Pro Leu Gly Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>121</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 CDR-H1</s223>
</s220>
</s200>
<s400> 121
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>122</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 CDR-H2</s223>
</s220>
</s200>
<s400> 122
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>123</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 CDR-H3</s223>
</s220>
</s200>
<s400> 123
Glu Ala Val Pro Leu Gly Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>124</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 VH region</s223>
</s220>
</s200>
<s400> 124
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Ser
            20                  25                  30
Arg Tyr His Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>125</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 CDR-H1</s223>
</s220>
</s200>
<s400> 125
Asn Ser Arg Tyr His Trp Gly
1               5
</s400>
<s200>
<s210>126</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 CDR-H2</s223>
</s220>
</s200>
<s400> 126
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>127</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 CDR-H3</s223>
</s220>
</s200>
<s400> 127
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>128</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 VH region</s223>
</s220>
</s200>
<s400> 128
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Glu Ala Ile Leu Gly Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>129</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 CDR-H1</s223>
</s220>
</s200>
<s400> 129
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>130</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 CDR-H2</s223>
</s220>
</s200>
<s400> 130
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>131</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 CDR-H3</s223>
</s220>
</s200>
<s400> 131
Glu Glu Ala Ile Leu Gly Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>132</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 VH region</s223>
</s220>
</s200>
<s400> 132
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Gly Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>133</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 CDR-H1</s223>
</s220>
</s200>
<s400> 133
Ser Ser Gly Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>134</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 CDR-H2</s223>
</s220>
</s200>
<s400> 134
Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>135</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 CDR-H3</s223>
</s220>
</s200>
<s400> 135
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>136</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 VH region</s223>
</s220>
</s200>
<s400> 136
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Phe Asp Val Ser Leu Gly Gly Gly Ser Asp Thr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>137</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 CDR-H1</s223>
</s220>
</s200>
<s400> 137
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>138</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 CDR-H2</s223>
</s220>
</s200>
<s400> 138
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>139</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 CDR-H3</s223>
</s220>
</s200>
<s400> 139
Phe Asp Val Ser Leu Gly Gly Gly Ser Asp Thr
1               5                   10
</s400>
<s200>
<s210>140</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 VH region</s223>
</s220>
</s200>
<s400> 140
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Ser
            20                  25                  30
Arg Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Gly Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>141</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 CDR-H1</s223>
</s220>
</s200>
<s400> 141
Asn Ser Arg Tyr His Trp Gly
1               5
</s400>
<s200>
<s210>142</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 CDR-H2</s223>
</s220>
</s200>
<s400> 142
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Gly
1               5                   10                  15
</s400>
<s200>
<s210>143</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 CDR-H3</s223>
</s220>
</s200>
<s400> 143
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>144</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 VH region</s223>
</s220>
</s200>
<s400> 144
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Gly Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Asn Tyr Arg Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>145</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 CDR-H1</s223>
</s220>
</s200>
<s400> 145
Ser Ser Gly Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>146</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 CDR-H2</s223>
</s220>
</s200>
<s400> 146
Asp Ile Asn Tyr Arg Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>147</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 CDR-H3</s223>
</s220>
</s200>
<s400> 147
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>148</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 VH region</s223>
</s220>
</s200>
<s400> 148
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Arg Asn Ser
            20                  25                  30
Arg Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Gly Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>149</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 CDR-H1</s223>
</s220>
</s200>
<s400> 149
Asn Ser Arg Tyr His Trp Gly
1               5
</s400>
<s200>
<s210>150</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 CDR-H2</s223>
</s220>
</s200>
<s400> 150
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Gly
1               5                   10                  15
</s400>
<s200>
<s210>151</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 CDR-H3</s223>
</s220>
</s200>
<s400> 151
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>152</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 VH region</s223>
</s220>
</s200>
<s400> 152
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Gly Val Pro Leu Gly Gly Gly Ala Asp Lys Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>153</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 CDR-H1</s223>
</s220>
</s200>
<s400> 153
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>154</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 CDR-H2</s223>
</s220>
</s200>
<s400> 154
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>155</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 CDR-H3</s223>
</s220>
</s200>
<s400> 155
Glu Gly Val Pro Leu Gly Gly Gly Ala Asp Lys
1               5                   10
</s400>
<s200>
<s210>156</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 VH region</s223>
</s220>
</s200>
<s400> 156
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>157</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 CDR-H1</s223>
</s220>
</s200>
<s400> 157
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>158</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 CDR-H2</s223>
</s220>
</s200>
<s400> 158
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>159</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 CDR-H3</s223>
</s220>
</s200>
<s400> 159
Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys
1               5                   10
</s400>
<s200>
<s210>160</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 VH region</s223>
</s220>
</s200>
<s400> 160
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>161</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 CDR-H1</s223>
</s220>
</s200>
<s400> 161
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>162</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 CDR-H2</s223>
</s220>
</s200>
<s400> 162
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>163</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 CDR-H3</s223>
</s220>
</s200>
<s400> 163
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>164</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 VH region</s223>
</s220>
</s200>
<s400> 164
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>165</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 CDR-H1</s223>
</s220>
</s200>
<s400> 165
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>166</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 CDR-H2</s223>
</s220>
</s200>
<s400> 166
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>167</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 CDR-H3</s223>
</s220>
</s200>
<s400> 167
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>168</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 VH region</s223>
</s220>
</s200>
<s400> 168
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>169</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 CDR-H1</s223>
</s220>
</s200>
<s400> 169
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>170</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 CDR-H2</s223>
</s220>
</s200>
<s400> 170
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>171</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 CDR-H3</s223>
</s220>
</s200>
<s400> 171
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
</s400>
<s200>
<s210>172</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B VH region</s223>
</s220>
</s200>
<s400> 172
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Asn Tyr Asn Gly Asn Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Asp Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>173</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B CDR-H1</s223>
</s220>
</s200>
<s400> 173
Ser Ser Asn Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>174</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B CDR-H2</s223>
</s220>
</s200>
<s400> 174
Asp Ile Asn Tyr Asn Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>175</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B CDR-H3</s223>
</s220>
</s200>
<s400> 175
Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Asp
1               5                   10
</s400>
<s200>
<s210>176</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F VH region</s223>
</s220>
</s200>
<s400> 176
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>177</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F CDR-H1</s223>
</s220>
</s200>
<s400> 177
Ser Gly Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>178</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F CDR-H2</s223>
</s220>
</s200>
<s400> 178
Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>179</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F CDR-H3</s223>
</s220>
</s200>
<s400> 179
Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser
1               5                   10
</s400>
<s200>
<s210>180</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H VH region</s223>
</s220>
</s200>
<s400> 180
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Gly Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Asn Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Asn Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Glu Val Ile Leu Gly Gly Gly Ala Asp Gln Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>181</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H CDR-H1</s223>
</s220>
</s200>
<s400> 181
Ser Ser Gly Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>182</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H CDR-H2</s223>
</s220>
</s200>
<s400> 182
Asp Ile Tyr Tyr Thr Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Asn
1               5                   10                  15
</s400>
<s200>
<s210>183</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H CDR-H3</s223>
</s220>
</s200>
<s400> 183
Glu Glu Val Ile Leu Gly Gly Gly Ala Asp Gln
1               5                   10
</s400>
<s200>
<s210>184</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E VH region</s223>
</s220>
</s200>
<s400> 184
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Glu Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>185</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E CDR-H1</s223>
</s220>
</s200>
<s400> 185
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>186</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E CDR-H2</s223>
</s220>
</s200>
<s400> 186
Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>187</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E CDR-H3</s223>
</s220>
</s200>
<s400> 187
Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Glu
1               5                   10
</s400>
<s200>
<s210>188</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C VH region</s223>
</s220>
</s200>
<s400> 188
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Gln Ala Val Met Tyr Gly Gly Gly Ser Asp Asn Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>189</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C CDR-H1</s223>
</s220>
</s200>
<s400> 189
Ser Gly Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>190</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C CDR-H2</s223>
</s220>
</s200>
<s400> 190
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>191</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C CDR-H3</s223>
</s220>
</s200>
<s400> 191
Gln Ala Val Met Tyr Gly Gly Gly Ser Asp Asn
1               5                   10
</s400>
<s200>
<s210>192</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E VH region</s223>
</s220>
</s200>
<s400> 192
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Asp Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Met Ile Leu Gly Gly Gly Ala Asp Asn Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>193</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E CDR-H1</s223>
</s220>
</s200>
<s400> 193
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>194</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E CDR-H2</s223>
</s220>
</s200>
<s400> 194
Asp Ile Tyr Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Asp
1               5                   10                  15
</s400>
<s200>
<s210>195</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E CDR-H3</s223>
</s220>
</s200>
<s400> 195
Glu Asp Met Ile Leu Gly Gly Gly Ala Asp Asn
1               5                   10
</s400>
<s200>
<s210>196</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B VH region</s223>
</s220>
</s200>
<s400> 196
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>197</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B CDR-H1</s223>
</s220>
</s200>
<s400> 197
Ser Ser Asn Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>198</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B CDR-H2</s223>
</s220>
</s200>
<s400> 198
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>199</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B CDR-H3</s223>
</s220>
</s200>
<s400> 199
Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser
1               5                   10
</s400>
<s200>
<s210>200</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E VH region</s223>
</s220>
</s200>
<s400> 200
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Ser Gly
            20                  25                  30
Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Met Tyr Gly Gly Gly Gly Asp Ser Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>201</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E CDR-H1</s223>
</s220>
</s200>
<s400> 201
Ser Gly Asn Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>202</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E CDR-H2</s223>
</s220>
</s200>
<s400> 202
Asp Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>203</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E CDR-H3</s223>
</s220>
</s200>
<s400> 203
Glu Asp Val Met Tyr Gly Gly Gly Gly Asp Ser
1               5                   10
</s400>
<s200>
<s210>204</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A VH region</s223>
</s220>
</s200>
<s400> 204
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Asn Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Ser Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>205</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A CDR-H1</s223>
</s220>
</s200>
<s400> 205
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>206</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A CDR-H2</s223>
</s220>
</s200>
<s400> 206
Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Asn
1               5                   10                  15
</s400>
<s200>
<s210>207</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A CDR-H3</s223>
</s220>
</s200>
<s400> 207
Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Ser
1               5                   10
</s400>
<s200>
<s210>208</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A VH region</s223>
</s220>
</s200>
<s400> 208
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Lys Phe Gly Gly Gly Ala Asp Leu Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>209</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A CDR-H1</s223>
</s220>
</s200>
<s400> 209
Ser Ser Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>210</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A CDR-H2</s223>
</s220>
</s200>
<s400> 210
Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
</s400>
<s200>
<s210>211</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A CDR-H3</s223>
</s220>
</s200>
<s400> 211
Glu Asp Val Lys Phe Gly Gly Gly Ala Asp Leu
1               5                   10
</s400>
<s200>
<s210>212</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H VH region</s223>
</s220>
</s200>
<s400> 212
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Asn Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Asn Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>213</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H CDR-H1</s223>
</s220>
</s200>
<s400> 213
Ser Gly Ser Tyr Tyr Trp Gly
1               5
</s400>
<s200>
<s210>214</s210>
<s211>16</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H CDR-H2</s223>
</s220>
</s200>
<s400> 214
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Asn
1               5                   10                  15
</s400>
<s200>
<s210>215</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H CDR-H3</s223>
</s220>
</s200>
<s400> 215
Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Asn
1               5                   10
</s400>
<s200>
<s210>216</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 VL region</s223>
</s220>
</s200>
<s400> 216
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Thr Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>217</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 CDR-L1</s223>
</s220>
</s200>
<s400> 217
Ser Gly Asp Thr Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>218</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 CDR-L2</s223>
</s220>
</s200>
<s400> 218
Glu Asp Ser Glu Arg Pro Ser
1               5
</s400>
<s200>
<s210>219</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.13 CDR-L3</s223>
</s220>
</s200>
<s400> 219
Gln Ala Trp Asp Ser Glu Thr Gly Val
1               5
</s400>
<s200>
<s210>220</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 VL region</s223>
</s220>
</s200>
<s400> 220
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Glu Arg Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Phe Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>221</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 CDR-L1</s223>
</s220>
</s200>
<s400> 221
Ser Gly Glu Arg Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>222</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 CDR-L2</s223>
</s220>
</s200>
<s400> 222
Glu Asp Phe Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>223</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.16 CDR-L3</s223>
</s220>
</s200>
<s400> 223
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>224</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 VL region</s223>
</s220>
</s200>
<s400> 224
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Val Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>225</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 CDR-L1</s223>
</s220>
</s200>
<s400> 225
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>226</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 CDR-L2</s223>
</s220>
</s200>
<s400> 226
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>227</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.38 CDR-L3</s223>
</s220>
</s200>
<s400> 227
Gln Ala Trp Asp Arg Asp Val Gly Val
1               5
</s400>
<s200>
<s210>228</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.4 VL region</s223>
</s220>
</s200>
<s400> 228
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>229</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.4 CDR-L1</s223>
</s220>
</s200>
<s400> 229
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>230</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.4 CDR-L2</s223>
</s220>
</s200>
<s400> 230
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>231</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.4 CDR-L3</s223>
</s220>
</s200>
<s400> 231
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>232</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 VL region</s223>
</s220>
</s200>
<s400> 232
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>233</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 CDR-L1</s223>
</s220>
</s200>
<s400> 233
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>234</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 CDR-L2</s223>
</s220>
</s200>
<s400> 234
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>235</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.11 CDR-L3</s223>
</s220>
</s200>
<s400> 235
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>236</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 VL region</s223>
</s220>
</s200>
<s400> 236
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>237</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 CDR-L1</s223>
</s220>
</s200>
<s400> 237
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>238</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 CDR-L2</s223>
</s220>
</s200>
<s400> 238
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>239</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.14 CDR-L3</s223>
</s220>
</s200>
<s400> 239
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>240</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 VL region</s223>
</s220>
</s200>
<s400> 240
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>241</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 CDR-L1</s223>
</s220>
</s200>
<s400> 241
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>242</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 CDR-L2</s223>
</s220>
</s200>
<s400> 242
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>243</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.17 CDR-L3</s223>
</s220>
</s200>
<s400> 243
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>244</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 VL region</s223>
</s220>
</s200>
<s400> 244
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>245</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 CDR-L1</s223>
</s220>
</s200>
<s400> 245
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>246</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 CDR-L2</s223>
</s220>
</s200>
<s400> 246
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>247</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.18 CDR-L3</s223>
</s220>
</s200>
<s400> 247
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>248</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 VL region</s223>
</s220>
</s200>
<s400> 248
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>249</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 CDR-L1</s223>
</s220>
</s200>
<s400> 249
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>250</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 CDR-L2</s223>
</s220>
</s200>
<s400> 250
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>251</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.19 CDR-L3</s223>
</s220>
</s200>
<s400> 251
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>252</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 VL region</s223>
</s220>
</s200>
<s400> 252
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>253</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 CDR-L1</s223>
</s220>
</s200>
<s400> 253
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>254</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 CDR-L2</s223>
</s220>
</s200>
<s400> 254
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>255</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.22 CDR-L3</s223>
</s220>
</s200>
<s400> 255
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>256</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 VL region</s223>
</s220>
</s200>
<s400> 256
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>257</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 CDR-L1</s223>
</s220>
</s200>
<s400> 257
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>258</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 CDR-L2</s223>
</s220>
</s200>
<s400> 258
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>259</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.48 CDR-L3</s223>
</s220>
</s200>
<s400> 259
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>260</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 VL region</s223>
</s220>
</s200>
<s400> 260
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>261</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 CDR-L1</s223>
</s220>
</s200>
<s400> 261
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>262</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 CDR-L2</s223>
</s220>
</s200>
<s400> 262
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>263</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.65 CDR-L3</s223>
</s220>
</s200>
<s400> 263
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>264</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 VL region</s223>
</s220>
</s200>
<s400> 264
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>265</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 CDR-L1</s223>
</s220>
</s200>
<s400> 265
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>266</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 CDR-L2</s223>
</s220>
</s200>
<s400> 266
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>267</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.66 CDR-L3</s223>
</s220>
</s200>
<s400> 267
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>268</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 VL region</s223>
</s220>
</s200>
<s400> 268
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>269</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 CDR-L1</s223>
</s220>
</s200>
<s400> 269
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                   10
</s400>
<s200>
<s210>270</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 CDR-L2</s223>
</s220>
</s200>
<s400> 270
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>271</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 CDR-L3</s223>
</s220>
</s200>
<s400> 271
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
</s400>
<s200>
<s210>272</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B VL region</s223>
</s220>
</s200>
<s400> 272
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>273</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B CDR-L1</s223>
</s220>
</s200>
<s400> 273
Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>274</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B CDR-L2</s223>
</s220>
</s200>
<s400> 274
Glu Asp Ser Thr Arg Pro Ser
1               5
</s400>
<s200>
<s210>275</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.2B CDR-L3</s223>
</s220>
</s200>
<s400> 275
Gln Ala Trp Asp Ser Glu Thr Gly Val
1               5
</s400>
<s200>
<s210>276</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F VL region</s223>
</s220>
</s200>
<s400> 276
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Gln Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Met Glu Ala Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr Val Leu
            100                 105
</s400>
<s200>
<s210>277</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F CDR-L1</s223>
</s220>
</s200>
<s400> 277
Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>278</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F CDR-L2</s223>
</s220>
</s200>
<s400> 278
Glu Asp Ser Gln Arg Pro Ser
1               5
</s400>
<s200>
<s210>279</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1F CDR-L3</s223>
</s220>
</s200>
<s400> 279
Gln Ala Trp Asp Met Glu Ala Gly Val
1               5
</s400>
<s200>
<s210>280</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C VL region</s223>
</s220>
</s200>
<s400> 280
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Ser Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>281</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C CDR-L1</s223>
</s220>
</s200>
<s400> 281
Ser Gly Asp Ser Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>282</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C CDR-L2</s223>
</s220>
</s200>
<s400> 282
Glu Asp Ser Glu Arg Pro Ser
1               5
</s400>
<s200>
<s210>283</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10C CDR-L3</s223>
</s220>
</s200>
<s400> 283
Gln Ala Trp Asp Ser Glu Thr Gly Val
1               5
</s400>
<s200>
<s210>284</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E VL region</s223>
</s220>
</s200>
<s400> 284
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Ala Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>285</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E CDR-L1</s223>
</s220>
</s200>
<s400> 285
Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>286</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E CDR-L2</s223>
</s220>
</s200>
<s400> 286
Glu Asp Ser Glu Arg Pro Ser
1               5
</s400>
<s200>
<s210>287</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10E CDR-L3</s223>
</s220>
</s200>
<s400> 287
Gln Ala Trp Asp Ser Glu Ala Gly Val
1               5
</s400>
<s200>
<s210>288</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E VL region</s223>
</s220>
</s200>
<s400> 288
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Ala Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>289</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E CDR-L1</s223>
</s220>
</s200>
<s400> 289
Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>290</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E CDR-L2</s223>
</s220>
</s200>
<s400> 290
Glu Asp Ser Glu Arg Pro Ser
1               5
</s400>
<s200>
<s210>291</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7E CDR-L3</s223>
</s220>
</s200>
<s400> 291
Gln Ala Trp Asp Ser Glu Ala Gly Val
1               5
</s400>
<s200>
<s210>292</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E VL region</s223>
</s220>
</s200>
<s400> 292
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Met Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Gln Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>293</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E CDR-L1</s223>
</s220>
</s200>
<s400> 293
Ser Gly Asp Met Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>294</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E CDR-L2</s223>
</s220>
</s200>
<s400> 294
Glu Asp Ser Gln Arg Pro Ser
1               5
</s400>
<s200>
<s210>295</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.5E CDR-L3</s223>
</s220>
</s200>
<s400> 295
Gln Ala Trp Asp Ser Glu Thr Gly Val
1               5
</s400>
<s200>
<s210>296</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B VL region</s223>
</s220>
</s200>
<s400> 296
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Gly Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Ser Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>297</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B CDR-L1</s223>
</s220>
</s200>
<s400> 297
Ser Gly Asp Gly Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>298</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B CDR-L2</s223>
</s220>
</s200>
<s400> 298
Glu Asp Ser Thr Arg Pro Ser
1               5
</s400>
<s200>
<s210>299</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.12B CDR-L3</s223>
</s220>
</s200>
<s400> 299
Gln Ala Trp Asp Ser Glu Ser Gly Val
1               5
</s400>
<s200>
<s210>300</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H VL region</s223>
</s220>
</s200>
<s400> 300
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Gly Glu Thr Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>301</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H CDR-L1</s223>
</s220>
</s200>
<s400> 301
Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>302</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H CDR-L2</s223>
</s220>
</s200>
<s400> 302
Glu Asp Ser Lys Arg Pro Ser
1               5
</s400>
<s200>
<s210>303</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.10H CDR-L3</s223>
</s220>
</s200>
<s400> 303
Gln Ala Trp Asp Gly Glu Thr Gly Val
1               5
</s400>
<s200>
<s210>304</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A VL region</s223>
</s220>
</s200>
<s400> 304
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Met Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Thr Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>305</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A CDR-L1</s223>
</s220>
</s200>
<s400> 305
Ser Gly Asp Met Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>306</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A CDR-L2</s223>
</s220>
</s200>
<s400> 306
Glu Asp Thr Asn Arg Pro Ser
1               5
</s400>
<s200>
<s210>307</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.6A CDR-L3</s223>
</s220>
</s200>
<s400> 307
Gln Ala Trp Asp Ser Glu Thr Gly Val
1               5
</s400>
<s200>
<s210>308</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A VL region</s223>
</s220>
</s200>
<s400> 308
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Ala Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Met Glu Thr Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>309</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A CDR-L1</s223>
</s220>
</s200>
<s400> 309
Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>310</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A CDR-L2</s223>
</s220>
</s200>
<s400> 310
Gln Asp Ala Met Arg Pro Ser
1               5
</s400>
<s200>
<s210>311</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.7A CDR-L3</s223>
</s220>
</s200>
<s400> 311
Gln Ala Trp Asp Met Glu Thr Gly Val
1               5
</s400>
<s200>
<s210>312</s210>
<s211>104</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H VL region</s223>
</s220>
</s200>
<s400> 312
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Val Gly Val
                85                  90                  95
Phe Gly Ser Gly Thr Lys Val Thr
            100
</s400>
<s200>
<s210>313</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H CDR-L1</s223>
</s220>
</s200>
<s400> 313
Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>314</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H CDR-L2</s223>
</s220>
</s200>
<s400> 314
Glu Asp Ser Met Arg Pro Ser
1               5
</s400>
<s200>
<s210>315</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.8H CDR-L3</s223>
</s220>
</s200>
<s400> 315
Gln Ala Trp Asp Ser Glu Val Gly Val
1               5
</s400>
<s200>
<s210>316</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.3 VH region</s223>
</s220>
</s200>
<s400> 316
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Ser Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Ile Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Ser Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>317</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.K3O VH region</s223>
</s220>
</s200>
<s400> 317
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>318</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.K42 VH region</s223>
</s220>
</s200>
<s400> 318
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gln Ser His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Met Ile Ser Tyr Asp Gly Thr Ile Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>319</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.9A VH region</s223>
</s220>
</s200>
<s400> 319
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Thr Ile Ser Tyr Asp Gly Arg Asn Lys Asp Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>320</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.8A VH region</s223>
</s220>
</s200>
<s400> 320
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>321</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.1A VH region</s223>
</s220>
</s200>
<s400> 321
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe His Ser His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Met Ile Ser Asp Asp Gly Arg Asn Lys Asp Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Arg Ala Ala Gly Gly Asn Val Gly Leu Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>322</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.5D VH region</s223>
</s220>
</s200>
<s400> 322
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ser Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Asp Ile Ser Val Asp Gly Ser Asn Lys Tyr Ser Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Arg Ala Ala Gly Gly Asn Val Gly Leu Asp Ser Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>323</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.3A VH region</s223>
</s220>
</s200>
<s400> 323
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>324</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.6B VH region</s223>
</s220>
</s200>
<s400> 324
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>325</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.3D VH region</s223>
</s220>
</s200>
<s400> 325
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Asp Ile Ser Gln Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Arg Ala Ala Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>326</s210>
<s211>119</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.4C VH region</s223>
</s220>
</s200>
<s400> 326
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser His
            20                  25                  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Asp Ile Ser Asn Asp Gly Arg Tyr Ala Tyr Ser Ala Asp Ser Val
    50                  55                  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80
Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
            100                 105                 110
Thr Met Val Thr Val Ser Ser
        115
</s400>
<s200>
<s210>327</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.3 VL region</s223>
</s220>
</s200>
<s400> 327
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Ala Asp Lys Leu Gly Thr Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Ala Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Leu Cys Gln Ser Trp Asp Arg Ser Asp Val Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105
</s400>
<s200>
<s210>328</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.L45 VL region</s223>
</s220>
</s200>
<s400> 328
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Ala Asp Glu Leu Gly Thr Gln Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Ala Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Ser Gly Val Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105
</s400>
<s200>
<s210>329</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.L73 VL region</s223>
</s220>
</s200>
<s400> 329
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Leu Gly Ser Gln Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Ala Gln Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Ser Gly Val Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105
</s400>
<s200>
<s210>330</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.3A VL region</s223>
</s220>
</s200>
<s400> 330
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Ala Asp Asn Leu Gly Glu Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Ala Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Ser Ser Gly Ala Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105
</s400>
<s200>
<s210>331</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.6B VL region</s223>
</s220>
</s200>
<s400> 331
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Ala Asp Asn Leu Gly Asn Gln Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Gly Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Trp Ser Gly Glu Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105
</s400>
<s200>
<s210>332</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.3D VL region</s223>
</s220>
</s200>
<s400> 332
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Ala Asp Lys Leu Gly Thr Lys Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Gly Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Gln Ser Gly Ala Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105
</s400>
<s200>
<s210>333</s210>
<s211>106</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody A10.4C VL region</s223>
</s220>
</s200>
<s400> 333
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Ala Asp Asn Leu Gly Asn Gln Tyr Val
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Gln Asp Gly Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Gly Ala Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105
</s400>
<s200>
<s210>334</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1 VH region</s223>
</s220>
</s200>
<s400> 334
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>335</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.1 VL region</s223>
</s220>
</s200>
<s400> 335
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Arg Val Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>336</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE1 VH region</s223>
</s220>
</s200>
<s400> 336
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe
65                  70                  75                  80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>337</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE1 VL region</s223>
</s220>
</s200>
<s400> 337
Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Leu Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>338</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE2 VH region</s223>
</s220>
</s200>
<s400> 338
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe
65                  70                  75                  80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>339</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE2 VL region</s223>
</s220>
</s200>
<s400> 339
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Arg Val Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>340</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE3 VH region</s223>
</s220>
</s200>
<s400> 340
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Tyr Leu Lys Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>341</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE3 VL region</s223>
</s220>
</s200>
<s400> 341
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Arg Val Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>342</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE4 VH region</s223>
</s220>
</s200>
<s400> 342
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>343</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE4 VL region</s223>
</s220>
</s200>
<s400> 343
Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Leu Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>344</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE5 VH region</s223>
</s220>
</s200>
<s400> 344
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>345</s210>
<s211>108</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE5 VL region</s223>
</s220>
</s200>
<s400> 345
Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1               5                   10                  15
Glu Lys Val Thr Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
            20                  25                  30
Ala Ser Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile
        35                  40                  45
Tyr Glu Asp Ser Lys Arg Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Asn Ser Leu Glu Ala
65                  70                  75                  80
Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
                85                  90                  95
Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
            100                 105
</s400>
<s200>
<s210>346</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE6 VH region</s223>
</s220>
</s200>
<s400> 346
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Tyr Leu Lys Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>347</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE6 VL region</s223>
</s220>
</s200>
<s400> 347
Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Leu Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>348</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE7 VH region</s223>
</s220>
</s200>
<s400> 348
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe
65                  70                  75                  80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>349</s210>
<s211>108</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE7 VL region</s223>
</s220>
</s200>
<s400> 349
Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1               5                   10                  15
Glu Lys Val Thr Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
            20                  25                  30
Ala Ser Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile
        35                  40                  45
Tyr Glu Asp Ser Lys Arg Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Asn Ser Leu Glu Ala
65                  70                  75                  80
Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
                85                  90                  95
Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
            100                 105
</s400>
<s200>
<s210>350</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE8 VH region</s223>
</s220>
</s200>
<s400> 350
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Tyr Leu Lys Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>351</s210>
<s211>108</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-SE8 VL region</s223>
</s220>
</s200>
<s400> 351
Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1               5                   10                  15
Glu Lys Val Thr Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
            20                  25                  30
Ala Ser Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile
        35                  40                  45
Tyr Glu Asp Ser Lys Arg Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Asn Ser Leu Glu Ala
65                  70                  75                  80
Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
                85                  90                  95
Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
            100                 105
</s400>
<s200>
<s210>352</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-FR1 VH region</s223>
</s220>
</s200>
<s400> 352
Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu
1               5                   10                  15
Ser Leu Lys Ile Ser Cys Lys Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Met Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Gln Val Thr Ile Ser Val Asp Thr Ser Phe Asn Thr Phe
65                  70                  75                  80
Phe Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Met Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>353</s210>
<s211>108</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-FR1 VL region</s223>
</s220>
</s200>
<s400> 353
Glu Tyr Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1               5                   10                  15
Glu Arg Ala Thr Leu Ser Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
            20                  25                  30
Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Val Ile
        35                  40                  45
Tyr Glu Asp Ser Lys Arg Pro Ser Asp Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60
Ser Asn Ser Gly Asp Glu Ala Thr Leu Thr Ile Ser Ser Leu Gln Ser
65                  70                  75                  80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
                85                  90                  95
Val Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
            100                 105
</s400>
<s200>
<s210>354</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-FR2 VH region</s223>
</s220>
</s200>
<s400> 354
Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1               5                   10                  15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
                85                  90                  95
Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110
Gln Gly Thr Thr Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>355</s210>
<s211>108</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9-FR2 VL region</s223>
</s220>
</s200>
<s400> 355
Asp Tyr Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1               5                   10                  15
Glu Arg Ala Thr Ile Asn Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
            20                  25                  30
Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Val Ile
        35                  40                  45
Tyr Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly
    50                  55                  60
Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Ser Ser Leu Gln Ala
65                  70                  75                  80
Glu Asp Val Ala Val Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
                85                  90                  95
Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
            100                 105
</s400>
<s200>
<s210>356</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 VH region</s223>
</s220>
</s200>
<s400> 356
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>357</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71 VL region</s223>
</s220>
</s200>
<s400> 357
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Tyr Gly Thr Lys Val Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>358</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71(M) VH region</s223>
</s220>
</s200>
<s400> 358
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>359</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71(M) VL region</s223>
</s220>
</s200>
<s400> 359
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>360</s210>
<s211>121</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71(L) VH region</s223>
</s220>
</s200>
<s400> 360
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45
Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95
Cys Ala Arg Gln Ala Leu Ala Leu Gly Gly Gly Ser Asp Lys Trp Gly
            100                 105                 110
Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>361</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>DLL4 antibody E9.71(L) VL region</s223>
</s220>
</s200>
<s400> 361
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15
Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45
Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
            100                 105
</s400>
<s200>
<s210>362</s210>
<s211>19</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 362
Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Gly
1               5                   10                  15
Ser Trp Ala
</s400>
<s200>
<s210>363</s210>
<s211>19</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 363
Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Arg
1               5                   10                  15
Val Trp Ala
</s400>
<s200>
<s210>364</s210>
<s211>19</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 364
Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1               5                   10                  15
Ser Glu Ala
</s400>
<s200>
<s210>365</s210>
<s211>19</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 365
Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1               5                   10                  15
Ser Glu Ala
</s400>
<s200>
<s210>366</s210>
<s211>22</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 366
Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1               5                   10                  15
Phe Pro Gly Ala Arg Cys
            20
</s400>
<s200>
<s210>367</s210>
<s211>22</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
</s200>
<s400> 367
Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1               5                   10                  15
Phe Pro Gly Ala Arg Cys
            20
</s400>
<s200>
<s210>368</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>E9.71(M) antibody cleavage site</s223>
</s220>
</s200>
<s400> 368
Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Gly
1               5                   10                  15
Ser Trp Ala Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
            20                  25                  30
</s400>
<s200>
<s210>369</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>E9.71(M)-1 antibody cleavage site</s223>
</s220>
</s200>
<s400> 369
Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Arg
1               5                   10                  15
Val Trp Ala Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
            20                  25                  30
</s400>
<s200>
<s210>370</s210>
<s211>30</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>E9.71(M)-2 antibody cleavage site</s223>
</s220>
</s200>
<s400> 370
Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1               5                   10                  15
Ser Glu Ala Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
            20                  25                  30
</s400>
<s200>
<s210>371</s210>
<s211>29</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>E9.71(M)-3 antibody cleavage site</s223>
</s220>
</s200>
<s400> 371
Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1               5                   10                  15
Ser Glu Ala Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
            20                  25
</s400>
<s200>
<s210>372</s210>
<s211>33</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>E9.71(M)-4 antibody cleavage site</s223>
</s220>
</s200>
<s400> 372
Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1               5                   10                  15
Phe Pro Gly Ala Arg Cys Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val
            20                  25                  30
Ser
</s400>
<s200>
<s210>373</s210>
<s211>32</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>E9.71(M)-5 antibody cleavage site</s223>
</s220>
</s200>
<s400> 373
Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1               5                   10                  15
Phe Pro Gly Ala Arg Cys Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
            20                  25                  30
</s400>
<s200>
<s210>374</s210>
<s211>4</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>CDR localization peptide</s223>
</s220>
</s200>
<s400> 374
Phe Gly Xaa Gly
1
</s400>
<s200>
<s210>375</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>CDR localization peptide</s223>
</s220>
</s200>
<s400> 375
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1               5
</s400>
<s200>
<s210>376</s210>
<s211>5</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>CDR localization peptide</s223>
</s220>
</s200>
<s400> 376
Leu Glu Trp Ile Gly
1               5
</s400>
<s200>
<s210>377</s210>
<s211>4</s211>
<s212>PRT</s212>
<s213>Artificial Sequence</s213>
<s220>
<s223>CDR localization peptide</s223>
</s220>
</s200>
<s400> 377
Trp Gly Xaa Gly
1
</s400>
</sequence-list-new-rules>
</sequence-cwu>
